Article Versions Notes

Kunz JB, Schlotmann A, Daubenbüchel A, Lobitz S, Jarisch A, Grosse R, Cario H, Oevermann L, Hakimeh D, Tagliaferri L, et al. Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. Journal of Clinical Medicine. 2021; 10(19):4543. https://doi.org/10.3390/jcm10194543

Kunz, Joachim B., Andreas Schlotmann, Andrea Daubenbüchel, Stephan Lobitz, Andrea Jarisch, Regine Grosse, Holger Cario, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, and et al. 2021. "Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome" Journal of Clinical Medicine 10, no. 19: 4543. https://doi.org/10.3390/jcm10194543

Kunz, J. B., Schlotmann, A., Daubenbüchel, A., Lobitz, S., Jarisch, A., Grosse, R., Cario, H., Oevermann, L., Hakimeh, D., Tagliaferri, L., & Kulozik, A. E. (2021). Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. Journal of Clinical Medicine, 10(19), 4543. https://doi.org/10.3390/jcm10194543